Eth Zurich

Alnylam Pharmaceuticals, Inc.

Christian Wolfrum

Akin Akinc

Erick Moran Carreira

Markus Stoffel

Tomoko Nakayama

Bettina Meissburger

David Konys

The present invention relates to compounds of formula I, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention, suppression or amelioration of a disease mediated by the ROR gamma receptor in a subject in need thereof, in particular diabetes and diabetes-related disorders, specifically type II diabetes, methods of their production, as well as methods of treatment or prevention of such diseases.

ROR gamma modulators

This invention relates to new formulated lipid particles (FLiPs) comprising at least one of a single or double stranded oligonucleotide, where the oligonucleotide has been conjugated to a lipophile and at least one of an emulsion or liposome to which the conjugated oligonucleotide has been aggregated, admixed or associated. These particles have surprisingly been shown to effectively deliver oligonucleotides to heart, lung and muscle where they effect gene silencing.

Compositions and methods for mediating RNAi in vivo

Growing community of inventors

Zurich, Switzerland

Christian Wolfrum